| False negative tests for SARS-CoV-2 infection—challenges and implications S Woloshin, N Patel, AS Kesselheim New England Journal of Medicine 383 (6), e38, 2020 | 1002 | 2020 |
| The high cost of prescription drugs in the United States: origins and prospects for reform AS Kesselheim, J Avorn, A Sarpatwari Jama 316 (8), 858-871, 2016 | 854 | 2016 |
| Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis AS Kesselheim, AS Misono, JL Lee, MR Stedman, MA Brookhart, ... Jama 300 (21), 2514-2526, 2008 | 736 | 2008 |
| Failure of investigational drugs in late-stage clinical development and publication of trial results TJ Hwang, D Carpenter, JC Lauffenburger, B Wang, JM Franklin, ... JAMA internal medicine 176 (12), 1826-1833, 2016 | 527 | 2016 |
| FDA approval and regulation of pharmaceuticals, 1983-2018 JJ Darrow, J Avorn, AS Kesselheim Jama 323 (2), 164-176, 2020 | 444 | 2020 |
| Regulation of medical devices in the United States and European Union DB Kramer, S Xu, AS Kesselheim The ethical challenges of emerging medical technologies, 41-48, 2020 | 374 | 2020 |
| Clinical decision support systems could be modified to reduce ‘alert fatigue’while still minimizing the risk of litigation AS Kesselheim, K Cresswell, S Phansalkar, DW Bates, A Sheikh Health affairs 30 (12), 2310-2317, 2011 | 337 | 2011 |
| Assessment of the clinical benefit of cancer drugs receiving accelerated approval B Gyawali, SP Hey, AS Kesselheim JAMA internal medicine 179 (7), 906-913, 2019 | 329 | 2019 |
| FDA regulation of mobile health technologies NG Cortez, IG Cohen, AS Kesselheim New England Journal of Medicine 371 (4), 372-379, 2014 | 323 | 2014 |
| Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility GC Alexander, S Emerson, AS Kesselheim Jama 325 (17), 1717-1718, 2021 | 315 | 2021 |
| Electronic medication packaging devices and medication adherence: a systematic review KD Checchi, KF Huybrechts, J Avorn, AS Kesselheim Jama 312 (12), 1237-1247, 2014 | 298 | 2014 |
| Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer AS Kesselheim, JA Myers, J Avorn Jama 305 (22), 2320-2326, 2011 | 294 | 2011 |
| Mitigating bias in machine learning for medicine KN Vokinger, S Feuerriegel, AS Kesselheim Communications medicine 1 (1), 25, 2021 | 291 | 2021 |
| Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis AS Kesselheim, MR Stedman, EJ Bubrick, JJ Gagne, AS Misono, JL Lee, ... Drugs 70 (5), 605-621, 2010 | 278 | 2010 |
| Contrast-induced nephropathy: how it develops, how to prevent it MR Rudnick, A Kesselheim, S Goldfarb Cleveland Clinic journal of medicine 73 (1), 75, 2006 | 258 | 2006 |
| Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts JS Yeh, JM Franklin, J Avorn, J Landon, AS Kesselheim JAMA internal medicine 176 (6), 763-768, 2016 | 248 | 2016 |
| Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study AS Kesselheim, B Wang, JM Franklin, JJ Darrow Bmj 351, 2015 | 238 | 2015 |
| A randomized study of how physicians interpret research funding disclosures AS Kesselheim, CT Robertson, JA Myers, SL Rose, V Gillet, KM Ross, ... New England Journal of Medicine 367 (12), 1119-1127, 2012 | 235 | 2012 |
| Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis KN Vokinger, TJ Hwang, T Grischott, S Reichert, A Tibau, T Rosemann, ... The Lancet Oncology 21 (5), 664-670, 2020 | 224 | 2020 |
| Innovative research methods for studying treatments for rare diseases: methodological review JJ Gagne, L Thompson, K O’Keefe, AS Kesselheim Bmj 349, 2014 | 224 | 2014 |
